Elan shareholders approve one of four proposals Elan shareholders have approved a share repurchase programme at an extraordinary general meeting in Dublin. Business • 17 Jun 13
Elan shareholders approve one of four proposals Elan shareholders have approved a share repurchase programme at an extraordinary general meeting in Dublin. Business • 17 Jun 13
Elan begins process of finding a buyer Elan is to begin the process of finding a buyer after the company said it had received a number of expressions of interest. Business • 14 Jun 13
Elan begins process of finding a buyer Elan is to begin the process of finding a buyer after the company said it had received a number of expressions of interest. Business • 14 Jun 13
Royalty granted injunction over change to Elan bid Royalty Pharma has been granted a High Court injunction which could save its hostile bid for Elan even if some votes go against it at a meeting of the Irish drug company's shareholders next week. Business • 13 Jun 13
Royalty granted injunction over change to Elan bid Royalty Pharma has been granted a High Court injunction which could save its hostile bid for Elan even if some votes go against it at a meeting of the Irish drug company's shareholders next week. Business • 13 Jun 13
Elan experience questioned by former board member A former board member of Elan has questioned the experience and competence of the company's management and claims its proposed transactions are "value destructive". Business • 12 Jun 13
Elan experience questioned by former board member A former board member of Elan has questioned the experience and competence of the company's management and claims its proposed transactions are "value destructive". Business • 12 Jun 13
Elan withdraws case against Royalty Pharma bid Elan has withdrawn its US lawsuit against Royalty Pharma over the amount of information provided in relation to its bid for the Irish biotech firm. Business • 11 Jun 13
Elan withdraws case against Royalty Pharma bid Elan has withdrawn its US lawsuit against Royalty Pharma over the amount of information provided in relation to its bid for the Irish biotech firm. Business • 11 Jun 13
Royalty Pharma raises bid for Elan Royalty Pharma today raised its hostile bid for Elan to a potential $8 billion, coming back for the third time after just 7.5% of shareholders accepted the last offer. Business • 07 Jun 13
Royalty Pharma raises bid for Elan Royalty Pharma today raised its hostile bid for Elan to a potential $8 billion, coming back for the third time after just 7.5% of shareholders accepted the last offer. Business • 07 Jun 13
Courts temporarily stop Royalty's bid for Elan Elan has gotten some relief from a US court, which has temporarily restrained investment firm Royalty Pharma from proceeding with its hostile bid for the company. Business • 04 Jun 13
Courts temporarily stop Royalty's bid for Elan Elan has gotten some relief from a US court, which has temporarily restrained investment firm Royalty Pharma from proceeding with its hostile bid for the company. Business • 04 Jun 13
Elan has 'Plan B' if shareholders reject deals Elan said it will lay out an alternative strategy if shareholders reject a string of planned deals. Business • 30 May 13
Elan has 'Plan B' if shareholders reject deals Elan said it will lay out an alternative strategy if shareholders reject a string of planned deals. Business • 30 May 13
Elan's board rejects Royalty Pharma's latest bid Elan’s board has unanimously rejected Royalty Pharma’s revised bid, saying it “substantially undervalues” the company. Business • 23 May 13
Elan's board rejects Royalty Pharma's latest bid Elan’s board has unanimously rejected Royalty Pharma’s revised bid, saying it “substantially undervalues” the company. Business • 23 May 13
Royalty Pharma raises Elan bid Royalty Pharma last night raised its hostile bid for Elan to $12.50 per share. Business • 21 May 13
Royalty Pharma raises Elan bid Royalty Pharma last night raised its hostile bid for Elan to $12.50 per share. Business • 21 May 13
Royalty Pharma submits Elan offer Royalty Pharma today formally submitted its $11.25 per share bid for Elan to the company's shareholders. Business • 02 May 13
Royalty Pharma submits Elan offer Royalty Pharma today formally submitted its $11.25 per share bid for Elan to the company's shareholders. Business • 02 May 13
Elan board rejects Royalty Pharma bid The board of Elan has unanimously rejected a formal bid from Royalty Pharma, saying the offer of $11.25 a share grossly undervalues the company. Business • 22 Apr 13
Elan board rejects Royalty Pharma bid The board of Elan has unanimously rejected a formal bid from Royalty Pharma, saying the offer of $11.25 a share grossly undervalues the company. Business • 22 Apr 13
Elan buyback reduces Royalty bid Elan said today that it bought back $1 billion of its shares at $11.25 a share. Business • 18 Apr 13
Elan buyback reduces Royalty bid Elan said today that it bought back $1 billion of its shares at $11.25 a share. Business • 18 Apr 13
Big US corporate deals drive 'Merger Monday' The more than $52 billion worth of deals announced yesterday made it the busiest "merger Monday" this year. Business • 16 Apr 13
Big US corporate deals drive 'Merger Monday' The more than $52 billion worth of deals announced yesterday made it the busiest "merger Monday" this year. Business • 16 Apr 13
Royalty Pharma offers new bid for Elan Royalty Pharma made a firm cash offer for Elan today of up to $12 per share, stepping up its efforts to take control of the Dublin based firm. Business • 15 Apr 13
Royalty Pharma offers new bid for Elan Royalty Pharma made a firm cash offer for Elan today of up to $12 per share, stepping up its efforts to take control of the Dublin based firm. Business • 15 Apr 13
Elan shareholders vote in favour of share buyback Elan shareholders have voted overwhelmingly in favour of a $1 billion share buyback scheme announced in February. Business • 12 Apr 13
Elan shareholders vote in favour of share buyback Elan shareholders have voted overwhelmingly in favour of a $1 billion share buyback scheme announced in February. Business • 12 Apr 13
Elan completes sale of Tysabri stake to Biogen Elan has closed the sale of its 50% stake in multiple sclerosis drug Tysabri. Business • 03 Apr 13
Elan completes sale of Tysabri stake to Biogen Elan has closed the sale of its 50% stake in multiple sclerosis drug Tysabri. Business • 03 Apr 13
Elan offers Tysabri dividend after Royalty bid Elan has said it will give shareholders 20% of the royalty rights for multiple sclerosis drug Tysabri. Business • 04 Mar 13
Elan offers Tysabri dividend after Royalty bid Elan has said it will give shareholders 20% of the royalty rights for multiple sclerosis drug Tysabri. Business • 04 Mar 13
